Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
NEWARK, Calif., Nov. 28, 2016 -- CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for indications with high unmet medical need, including rare and orphan diseases, today announced that management will participate in a fireside chat at the 28th Annual Piper Jaffray Healthcare Conference on November 30, 2016.
The audio portion of the fireside chat will be accessible live through the Investors page on the company’s website at http://ir.cymabay.com/events. A replay of the webcast will be available on the company’s website for 14 days following the event.
28th Annual Piper Jaffray Healthcare Conference
Date: Wednesday, November 30
Time: 3:00pm – 3:25pm Eastern Time
Place: The Lotte New York Palace Hotel
Webcast: http://ir.cymabay.com/events
About CymaBay
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company developing therapies to treat diseases with high unmet medical need, including serious rare and orphan disorders. MBX-8025 is a potent, selective, orally active PPARδ agonist. CymaBay has recently completed a Phase 2 study of MBX-8025 in patients with primary biliary cholangitis as well as a pilot Phase 2 study in patients with homozygous familial hypercholesterolemia, establishing proof-of-concept in both indications. Previously, a Phase 2 study of MBX-8025 in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile. Arhalofenate, CymaBay’s other product candidate, is a potential Urate-Lowering Anti-Flare Therapy that has completed five Phase 2 studies in gout patients. Arhalofenate has been found to reduce painful flares in joints while at the same time promoting excretion of uric acid by the kidney. This dual action addresses both the signs and symptoms of gout while managing the underlying pathophysiology of hyperuricemia.
For additional information about CymaBay visit www.cymabay.com.
Contact: Sujal Shah CymaBay Therapeutics, Inc. (510) 293-8800 [email protected] Hans Vitzthum LifeSci Advisors, LLC 212-915-2568 [email protected]
